Skip to content

The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study

The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06610045
Enrollment
400
Registered
2024-09-24
Start date
2024-10-15
Completion date
2025-03-12
Last updated
2025-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caregiver Subjective Burden, Multiple Myeloma, Quality of Life (QOL)

Keywords

quality of life, real-world, observational, myeloma, caregiver

Brief summary

The purpose of this observational study is to estimate the burden of multiple myeloma on patients and caregivers in terms of QoL. Additionally, this study will assess the correlation between QoL, obtained from commonly used and validated questionnaires, and the perceptions of both patients and caregivers respectively., obtain from a 10-point scale and a comment box.

Detailed description

Potential participants will be identified by Myeloma Canada using their database. Myeloma Canada is a registered non-profit organization created by, and for, Canadians impacted by multiple myeloma. As part of Myeloma Canada website, patients and caregivers can subscribe to a mailing list to receive their monthly newsletter and to participate in surveys. This database comprises about 5,000 individuals, including patients and caregivers. An e-mail will be sent to 600 patients and 200 caregivers randomly selected to invited them to participate in the survey. Interested participants will be invited to visit the Participant Portal on the PROxy website (https://periproxy.com/en), to sign the informed consent form and complete online questionnaires. Upon request, paper-based documents (i.e., informed consent form and questionnaires) can also be sent by mail. The following questionnaires will be used: Patients * Patient Information Questionnaire (i.e., baseline characteristics) * EORTC QLQ-C30 * EORTC QLQ-MY20 * EQ-5D-5L * ESAS-R * Patients Perspective Caregivers * Caregiver Information Questionnaire (i.e., baseline characteristics) * CarGOQoL * Caregivers Perspective If the sample size (i.e., 300 patients and 100 caregivers) is not reached one month after the first e-mail, an invitation e-mail will be sent to an additional 600 eligible patients and/or 200 caregivers randomly selected. This scheme of participant identification will be performed until the sample size is reached.

Interventions

OTHERNo intervention

No specific intervention is assess in this study.

Sponsors

PeriPharm
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. 18 years of age or older; 2. Part of the Myeloma Canada database; 1. Identified as a patient with MM or 2. Identified as a current caregiver of a patient with MM at the time of participation. 3. Ability to read and understand English or French; 4. Signature of informed consent form (ICF).

Exclusion criteria

No

Design outcomes

Primary

MeasureTime frame
To estimate quality of life of patients with myeloma and caregivers of patients with myelomaFrom enrollment until sample size is reached

Secondary

MeasureTime frame
To assess the correlation between QoL scores and perception of patients and caregivers respectivelyFrom recruitment until sample size is reached

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026